259 related articles for article (PubMed ID: 15765203)
21. Hyperglycosylated-hCG (h-hCG) and Down syndrome screening in the first and second trimesters of pregnancy.
Palomaki GE; Neveux LM; Haddow JE; Wyatt P
Prenat Diagn; 2007 Sep; 27(9):808-13. PubMed ID: 17590886
[TBL] [Abstract][Full Text] [Related]
22. Persistent trophoblast disease following partial molar pregnancy.
Wielsma S; Kerkmeijer L; Bekkers R; Pyman J; Tan J; Quinn M
Aust N Z J Obstet Gynaecol; 2006 Apr; 46(2):119-23. PubMed ID: 16638033
[TBL] [Abstract][Full Text] [Related]
23. Midtrimester maternal serum inhibin A levels after multifetal pregnancy reduction.
Chen HJ; Huang LW; Lin YH; Seow KM; Hsieh BC; Hwang JL; Tzeng CR
Prenat Diagn; 2007 May; 27(5):431-4. PubMed ID: 17295349
[TBL] [Abstract][Full Text] [Related]
24. Metastatic complete hydatidiform mole with a surviving coexistent twin. A case report.
Kauffman DE; Sutkin G; Heine RP; Watt-Morse M; Price FV
J Reprod Med; 1999 Feb; 44(2):131-4. PubMed ID: 10853445
[TBL] [Abstract][Full Text] [Related]
25. Down syndrome biochemical markers and screening for preeclampsia at first and second trimester: correlation with the week of onset and the severity.
Kang JH; Farina A; Park JH; Kim SH; Kim JY; Rizzo N; Elmakky A; Jun HS; Hahn WB; Cha DH
Prenat Diagn; 2008 Aug; 28(8):704-9. PubMed ID: 18655226
[TBL] [Abstract][Full Text] [Related]
26. First and second-trimester biochemical markers of chromosomal anomalies and their relationship to maternal haemoglobin levels.
Cowans NJ; Spencer K
Prenat Diagn; 2005 Aug; 25(8):693-9. PubMed ID: 16050001
[TBL] [Abstract][Full Text] [Related]
27. Natural history of twin pregnancy with complete hydatidiform mole and coexisting fetus.
Steller MA; Genest DR; Bernstein MR; Lage JM; Goldstein DP; Berkowitz RS
Obstet Gynecol; 1994 Jan; 83(1):35-42. PubMed ID: 8272304
[TBL] [Abstract][Full Text] [Related]
28. [Screening for Down syndrome using first-trimester combined screening followed by second trimester ultrasound examination in an unselected population].
Rozenberg P; Bussières L; Chevret S; Bernard JP; Malagrida L; Cuckle H; Chabry C; Durand-Zaleski I; Bidat L; Lacroix I; Moulis M; Roger M; Jacquemot MC; Bault JP; Boukobza P; Boccara P; Vialat F; Giudicelli Y; Ville Y
Gynecol Obstet Fertil; 2007 Apr; 35(4):303-11. PubMed ID: 17350315
[TBL] [Abstract][Full Text] [Related]
29. Integrated serum screening for Down syndrome in primary obstetric practice.
Knight GJ; Palomaki GE; Neveux LM; Smith DE; Kloza EM; Pulkkinen AJ; Williams J; Haddow JE
Prenat Diagn; 2005 Dec; 25(12):1162-7. PubMed ID: 16231402
[TBL] [Abstract][Full Text] [Related]
30. Serum free estriol and estriol glucuronide fractions in hydatidiform mole measured by radioimmunoassay.
Dawood MY; Brown JB; Newnam KL
Obstet Gynecol; 1977 Mar; 49(3):303-7. PubMed ID: 840458
[TBL] [Abstract][Full Text] [Related]
31. Apparently low maternal serum inhibin A levels in second-trimester screening.
Lambert-Messerlian GM; Keren DF; Raphtis CS; Byberg K; Canick JA
Prenat Diagn; 2005 Oct; 25(10):967-8. PubMed ID: 16193465
[No Abstract] [Full Text] [Related]
32. Low risk of relapse after achieving undetectable HCG levels in women with partial molar pregnancy.
Wolfberg AJ; Growdon WB; Feltmate CM; Goldstein DP; Genest DR; Chinchilla ME; Berkowitz RS; Lieberman ES
Obstet Gynecol; 2006 Aug; 108(2):393-6. PubMed ID: 16880311
[TBL] [Abstract][Full Text] [Related]
33. Adverse outcome of pregnancies with extremely high levels of maternal serum human chorionic gonadotropin.
Sharony R; Itzhaky D; Amiel A; Hershko A; Grinshpoon Y; Fejgin M
Fetal Diagn Ther; 2008; 23(3):233-6. PubMed ID: 18417984
[TBL] [Abstract][Full Text] [Related]
34. Serum human chorionic somatomammotropin in unaborted hydatidiform mole.
Dawood MY; Teoh ES
Obstet Gynecol; 1976 Feb; 47(2):183-8. PubMed ID: 1250540
[TBL] [Abstract][Full Text] [Related]
35. Screening for Down syndrome using first-trimester combined screening followed by second-trimester ultrasound examination in an unselected population.
Rozenberg P; Bussières L; Chevret S; Bernard JP; Malagrida L; Cuckle H; Chabry C; Durand-Zaleski I; Bidat L; Lacroix I; Moulis M; Roger M; Jacquemot MC; Bault JP; Boukobza P; Boccara P; Vialard F; Giudicelli Y; Ville Y
Am J Obstet Gynecol; 2006 Nov; 195(5):1379-87. PubMed ID: 16723105
[TBL] [Abstract][Full Text] [Related]
36. [Partial hydatidiform mole with significantly increased serum HCG levels in the triploidy syndrome].
Arnholdt H; Elser H; Dörmer P
Geburtshilfe Frauenheilkd; 1984 May; 44(5):328-32. PubMed ID: 6565615
[TBL] [Abstract][Full Text] [Related]
37. Serum progesterone monitoring in post-molar surveillance.
Vasilev SA; Schlaerth JB; Ahn C; Sauer MV
Gynecol Oncol; 1994 Sep; 54(3):288-91. PubMed ID: 7522199
[TBL] [Abstract][Full Text] [Related]
38. [The serum concentration of specific beta 1-glycoprotein in trophoblastic disease].
Radikov N
Akush Ginekol (Sofiia); 1989; 28(2):15-9. PubMed ID: 2548413
[TBL] [Abstract][Full Text] [Related]
39. Second-trimester levels of pregnancy-associated plasma protein-A and free beta-hCG in pregnancies with trisomy 13.
Spencer K; Crossley JA; Aitken DA; Nicolaides KH
Prenat Diagn; 2005 May; 25(5):358-61. PubMed ID: 15906423
[TBL] [Abstract][Full Text] [Related]
40. Repeated measurement of pregnancy-associated plasma protein-A (PAPP-A) in Down syndrome screening: a validation study.
Palomaki GE; Wright DE; Summers AM; Neveux LM; Meier C; O'donnell A; Huang T; Knight GJ; Haddow JE
Prenat Diagn; 2006 Aug; 26(8):730-9. PubMed ID: 16810709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
